Keyphrases
Preclinical Efficacy
100%
Lutetium-177 (177Lu)
100%
Human Kallikrein 2
100%
Prostate Cancer Theranostics
100%
Androgen Receptor
77%
Absorbed Dose
44%
Prostate Cancer
22%
Tumor Volume
22%
Ki-67
22%
High Linear Energy Transfer
22%
Therapeutic Efficacy
22%
Androgen Signaling
22%
Cancer Xenograft
22%
Androgen Receptor Expression
22%
Linear Energy Transfer
22%
Injected Activity
22%
Single-photon Emission Computed Tomography Imaging
22%
Tumor Accumulation
22%
Biokinetics
22%
Actinium-225
22%
Feed-forward Mechanism
22%
Tumor
11%
Molecular Analysis
11%
DNA Damage
11%
Single-photon Emission Computed Tomography (SPECT)
11%
Treatment Planning
11%
Protein Level
11%
Rodents
11%
Receptor Downregulation
11%
Prostate
11%
Therapeutic Mechanism
11%
Ablating
11%
Receptor-interacting Protein Kinase 1 (RIPK1)
11%
Clonal Lineages
11%
Organ-specific
11%
Radionuclides
11%
Prostate Cancer Cells
11%
Specific Activity
11%
Treatment Duration
11%
Tumor Response
11%
Expression Level
11%
Days of Treatment
11%
Male Mice
11%
Humanized
11%
Xenograft
11%
Tumor Tissue
11%
Myelotoxicity
11%
Androgens
11%
Ki-67 Expression
11%
Dosimetric
11%
Recurrent Tumor
11%
Digital Autoradiography
11%
Prostate-specific
11%
Downstream Effects
11%
Complete Blood Count
11%
Cross-reactivity
11%
Tumor Volume Reduction
11%
Target Molecule
11%
Senescence
11%
Life Expectancy
11%
Cell Retention
11%
Kallikrein
11%
Mouse Tumor
11%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
11%
LNCaP
11%
Low Accumulation
11%
Submandibular Gland
11%
Tumor-to-blood Ratio
11%
Specific Enzymes
11%
Multiple Injections
11%
Tumor Measurement
11%
Computed Tomography (CT) Imaging
11%
Hematological Side Effects
11%
Beta Emitters
11%
Catalytic Cleft
11%
Tumor Killing
11%
α-particle Therapy
11%
Nucleus Staining
11%
Radionuclide 177Lu
11%
Specific Uptake
11%
IgG1 Antibody
11%
Beta-emitting Radionuclides
11%
Sigma Factor
11%
Androgen Axis
11%
Lineage Selection
11%
MOBY Phantom
11%
Theranostic Agent
11%
Medicine and Dentistry
Neoplasm
100%
Prostate Cancer
100%
Androgen Receptor
100%
Lutetium 177
100%
Kallikrein
100%
Absorbed Dose
36%
Linear Energy Transfer
36%
Single-Photon Emission Computed Tomography
27%
Actinium 225
27%
Combination Therapy
18%
Radioisotope
18%
Androgen
18%
Receptor Expression
18%
Tumor Xenograft
18%
Galactose
18%
Treatment Planning
9%
Cancer Cell
9%
Cleft
9%
Tumor Recurrence
9%
Xenograft
9%
Bone Marrow Toxicity
9%
Side Effect
9%
Blood Cell
9%
Cell Count
9%
Autoradiograph
9%
DNA Damage Response
9%
Life Expectancy
9%
Receptor Protein
9%
Submandibular Gland
9%
Cross Reaction
9%
Immunoglobulin G1 Antibody
9%
Particle Therapy
9%
Targeting Protein
9%
Receptor Upregulation
9%
Volumetric Tumor Measurement
9%
Hexachlorophene
9%
Diseases
9%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Prostate Cancer
100%
Kallikrein
100%
Lutetium 177
100%
Androgen Receptor
91%
Actinium 225
25%
Combination Therapy
16%
Radioisotope
16%
Androgen
16%
Galactose
16%
Receptor Protein
8%
Side Effect
8%
Tumor Recurrence
8%
Autoradiography
8%
Life Expectancy
8%
Immunoglobulin G1 Antibody
8%
Bone Marrow Toxicity
8%
Hexachlorophene
8%
Diseases
8%